Trial Profile
A phase I dose-ranging study of the safety, tolerability, and immunogenicity of the Merck trivalent adenovirus serotype 5 HIV-1 gag/pol/nef vaccine (MRKAd5 HIV-1 gag/pol/nef) in a prime-boost regimen in healthy adults
Status:
Not stated
Phase of Trial:
Phase I
Latest Information Update: 08 Feb 2006
Price :
$35
*
At a glance
- Drugs V 520 (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 08 Feb 2006 New trial record.